Claire Meyniel

Claire Meyniel

Auto-generated profile, based on publicly available information

Claire Meyniel

Neuro-ophtalmologiste, Groupe Ophtalliance, Clinique Jules Verne, 2 route de Paris, 44000 Nantes, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Frontiers in Systems Neuroscience
Verified
Journal Article
Open access
CMClaire Meyniel
Claire Meyniel
BBBahram Bodaghi
Bahram Bodaghi
PRPierre-Yves Robert
Pierre-Yves Robert
Low vision is a condition caused by eye or brain disease, in which visual acuity is 20/70 (3/10 or 6/18) or poorer in the better-seeing eye and cannot be corrected or improved with regular eyeglasses. It impacts personal ability to perform vision-dependent tasks as activities of daily living, walking, reading or using a computer. Rehabilitation is a multidisciplinary training dedicated to improve patients’ functional abilities and quality of life. It has to be personalized to every individual situation, whatever the underlying pathology.

25 November 2016 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
TSTim Spelman
Tim Spelman
CMClaire Meyniel
Claire Meyniel
JRJuan Rojas
Juan Rojas
ALAlessandra Lugaresi
Alessandra Lugaresi
GIGuillermo Izquierdo
Guillermo Izquierdo
OIon behalf of the MSBasis (an MSBase Substudy) Investigators
on behalf of the MSBasis (an MSBase Substudy) Investigators
Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). Objective: To examine determinants of second attack and validate a prognostic nomogram for individualised risk assessment of clinical conversion. Methods: Patients with CIS were prospectively followed up in the MSBase Incident Study. Predictors of clinical conversion were analysed using Cox proportional hazards regression. Prognostic nomograms were derived to calculate conversion probability and validated using concordance indices. Results: A total of 3296 patients from 50 clinics in 22 countries were followed up for a median (inter-quartile range (IQR)) of 1.92 years (0.90, 3.71). In all, 1953 (59.3%) patients recorded a second attack. Higher Expanded Disability Status Scale (EDSS) at baseline, first symptom location, oligoclonal bands and various brain and spinal magnetic resonance imaging (MRI) metrics were all predictors of conversion. Conversely, older age and DMD exposure post-CIS were associated with reduced rates. Prognostic nomograms demonstrated high concordance between estimated and observed conversion probabilities. Conclusion: This multinational study shows that age at CIS onset, DMD exposure, EDSS, multiple brain and spinal MRI criteria and oligoclonal bands are associated with shorter time to relapse. Nomogram assessment may be useful in clinical practice for estimating future clinical conversion.

25 June 2018 in Behavioural Neurology
Verified
Journal Article
Open access
PDF file
CMClaire Meyniel
Claire Meyniel
DSDalila Samri
Dalila Samri
FSFarah Stefano
Farah Stefano
JCJoel Crevoisier
Joel Crevoisier
FBFlorence Bonté
Florence Bonté
SEStéphane Epelbaum
Stéphane Epelbaum
We evaluated the cognitive status of visually impaired patients referred to low vision rehabilitation (LVR) based on a standard cognitive battery and a new evaluation tool, named the COGEVIS, which can be used to assess patients with severe visual deficits. We studied patients aged 60 and above, referred to the LVR Hospital in Paris. Neurological and cognitive evaluations were performed in an expert memory center. Thirty-eight individuals, 17 women and 21 men with a mean age of 70.3 ± 1.3 years and a mean visual acuity of 0.12 ± 0.02, were recruited over a one-year period. Sixty-three percent of participants had normal cognitive status. Cognitive impairment was diagnosed in 37.5% of participants. The COGEVIS score cutoff point to screen for cognitive impairment was 24 (maximum score of 30) with a sensitivity of 66.7% and a specificity of 95%. Evaluation following 4 months of visual rehabilitation showed an improvement of Instrumental Activities of Daily Living (p=0.004), National Eye Institute Visual Functioning Questionnaire (p=0.035), and Montgomery–Åsberg Depression Rating Scale (p=0.037). This study introduces a new short test to screen for cognitive impairment in visually impaired patients.

1 March 2020 in Revue Francophone d'Orthoptie
Verified
Journal Article
Closed access
CMClaire Meyniel
Claire Meyniel

1 July 2008 in Brain Stimulation
Verified
Journal Article
Closed access
LBL. Barbin
L. Barbin
CLC. Leux
C. Leux
CMC. Meyniel
C. Meyniel
NJN'Guyen J.
N'Guyen J.
YPY. Pereon
Y. Pereon
PDP. Damier
P. Damier